Literature DB >> 27340029

In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin.

Sophie Geboers1, Jef Stappaerts1, Jan Tack2, Pieter Annaert1, Patrick Augustijns3.   

Abstract

Simvastatin (SV) is marketed as a lactone ester prodrug which is hydrolyzed to the active simvastatin hydroxyacid (SVA). SV is characterized by a low solubility and undergoes extensive first-pass metabolism. In this study, the influence of the upper gastrointestinal environment on the intraluminal behavior of simvastatin was investigated by a series of in vitro experiments. Dissolution, stability and two-stage dissolution tests were performed using simulated and human gastrointestinal fluids. The dissolution studies revealed a relatively slow dissolution of SV as well as conversion of SV to SVA. The hydrolysis of SV was further examined and stability studies indicated a faster conversion in gastric fluids than in intestinal fluids. These isolated phenomena were then confirmed by the more integrative two-stage dissolution studies. To estimate the predictive value of the in vitro tests, an additional in vivo study was performed in which the gastrointestinal concentration-time profiles also revealed a slow dissolution of SV and faster degradation of SV to SVA in the stomach than in the intestinal tract. However, the plasma concentrations of SV and SVA did not directly correlate with the observed gastrointestinal concentrations, suggesting that gut wall and hepatic metabolism have a greater impact on systemic exposure of SV than the intraluminal interconversion between SV and SVA.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Clinical trial; Gastrointestinal behavior; Human gastrointestinal fluids; Prodrug; Simvastatin; Simvastatin acid

Mesh:

Substances:

Year:  2016        PMID: 27340029     DOI: 10.1016/j.ijpharm.2016.06.048

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

Review 1.  Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles.

Authors:  Nebojša Pavlović; Svetlana Goločorbin-Kon; Maja Ðanić; Bojan Stanimirov; Hani Al-Salami; Karmen Stankov; Momir Mikov
Journal:  Front Pharmacol       Date:  2018-11-08       Impact factor: 5.810

2.  Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression.

Authors:  Yuyan Zhang; Jiusui Huang; Yapeng Huang; Shike Zhang; Weizhou Wu; Hui Long; Xiaolu Duan; Yongchang Lai; Wenqi Wu
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.